DBV Technologies Reports Q2 2026 Financial Results and FDA BLA Progress.
DBV Technologies reported cash and cash equivalents of $174.9 million and continues FDA engagement for the VIASKIN Peanut Patch, anticipating a third-quarter 2026 BLA submission.
View filing at SEC.gov →